Merck & Co., Inc. (MRK)
A+
Pipeline Grade
Financial Position (from SEC Filings)
$5,398.0M
Cash & Equivalents
$3,918.0M
Quarterly Burn Rate
$305,122M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (40 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
ASPARAGINASE
ELSPAR |
APPROVED | — |
|
CHLOROTHIAZIDE, RESERPINE
DIUPRES-250 |
NDA | — |
|
BENZTROPINE MESYLATE
COGENTIN |
NDA | — |
|
ANILERIDINE HYDROCHLORIDE
LERITINE |
NDA | — |
|
DILTIAZEM MALATE
TIAMATE |
NDA | — |
|
CORTISONE ACETATE
CORTONE |
NDA | — |
|
DIFLUNISAL
DOLOBID |
NDA | — |
|
ANILERIDINE PHOSPHATE
LERITINE |
NDA | — |
|
MANNITOL
MANNITOL 25% |
NDA | — |
|
NORFLOXACIN
NOROXIN |
NDA | — |
|
HYDROXOCOBALAMIN
ALPHAREDISOL |
NDA | — |
|
CYPROHEPTADINE HYDROCHLORIDE
PERIACTIN |
NDA | — |
|
ISOFLUROPHATE
FLOROPRYL |
NDA | — |
|
AMILORIDE HYDROCHLORIDE, HYDROCHLOROTHIAZIDE
MODURETIC 5-50 |
NDA | — |
|
CASPOFUNGIN ACETATE
CANCIDAS |
NDA | — |
|
DEXAMETHASONE SODIUM PHOSPHATE, NEOMYCIN SULFATE
NEODECADRON |
NDA | — |
|
NEOMYCIN SULFATE, PREDNISOLONE SODIUM PHOSPHATE
NEO-HYDELTRASOL |
NDA | — |
|
METARAMINOL BITARTRATE
ARAMINE |
NDA | — |
|
SULINDAC
CLINORIL |
NDA | — |
|
HYDROCHLOROTHIAZIDE, TIMOLOL MALEATE
TIMOLIDE 10-25 |
NDA | — |
|
CEFOXITIN SODIUM
MEFOXIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER |
NDA | — |
|
AMINOHIPPURATE SODIUM
AMINOHIPPURATE SODIUM |
NDA | — |
|
PROBENECID
BENEMID |
NDA | — |
|
HYDROCHLOROTHIAZIDE
HYDRODIURIL |
NDA | — |
|
CHLOROTHIAZIDE, METHYLDOPA
ALDOCLOR-150 |
NDA | — |
|
DEXAMETHASONE SODIUM PHOSPHATE, LIDOCAINE HYDROCHLORIDE
DECADRON W/ XYLOCAINE |
NDA | — |
|
HYDROCHLOROTHIAZIDE, LISINOPRIL
PRINZIDE |
NDA | — |
|
ROFECOXIB
VIOXX |
NDA | — |
|
METHYLDOPA
ALDOMET |
NDA | — |
|
HEXYLCAINE HYDROCHLORIDE
CYCLAINE |
NDA | — |
|
HYDROCHLOROTHIAZIDE, RESERPINE
HYDROPRES 50 |
NDA | Acute Bacterial Gastroenteritis, Acute Hematogenous Osteomyelitis, Acute Lymphoblastic Leukemia, Acute Lymphoid Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse, Acute Pain, Acute-graft-versus-host Disease, Adenocarcinoma, Advanced Adult Hepatocellular Carcinoma, Advanced Cancer, Advanced Cancers Associated With Mesothelin Expression, Advanced Gastric Cancer, Advanced Malignant Solid Neoplasm, Advanced Prostate Cancer, Advanced Renal Cell Carcinoma, Advanced Solid Tumors, Aging, Alveolar Soft Part Sarcoma (ASPS), Anemia, Anovulation, Antimicrobial Prophylaxis, Asthma, Atherosclerosis, B-Thalassemia, Bacteremia, Bacterial Endocarditis, Bacterial Infection, Bacterial Infections, Beta-Thalassemia, Biliary Tract Cancer, Bladder Pain Syndrome, Blood Loss, Surgical, Bloodloss, Bloodstream Infection, Bowel Dysfunction, BRAF V600E-mutant Metastatic Colorectal Cancer, Breast Cancer, Burkitt Lymphoma, Cancer, Cancer Metastatic, Cancer, Advanced Solid Tumors, Candidemia, Candidiasis, Vulvovaginal, Ca |
|
CILASTATIN SODIUM, IMIPENEM
PRIMAXIN |
NDA | — |
|
METHYLDOPATE HYDROCHLORIDE
ALDOMET |
NDA | — |
|
DEXAMETHASONE ACETATE
DECADRON-LA |
NDA | — |
|
DEMECARIUM BROMIDE
HUMORSOL |
NDA | — |
|
HYDROCORTISONE SODIUM PHOSPHATE
HYDROCORTONE |
NDA | — |
|
LOVASTATIN
MEVACOR |
NDA | — |
|
HYDROCHLOROTHIAZIDE, METHYLDOPA
ALDORIL D30 |
NDA | — |
|
COLCHICINE, PROBENECID
COLBENEMID |
NDA | — |
|
PREDNISOLONE TEBUTATE
HYDELTRA-TBA |
NDA | — |
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-08-05 | Phase2 Readout | — |
| 2026-08-17 | Pdufa | — |
| 2026-10-31 | Phase2 Readout | — |
| 2026-11-19 | Phase1 Readout | — |
| 2026-12-01 | Phase2 Readout | — |
| 2026-12-01 | Phase1 Readout | — |
| 2026-12-31 | Phase1 Readout | — |
| 2027-02-26 | Phase2 Readout | — |
| 2027-04-29 | Phase2 Readout | — |
| 2027-06-01 | Phase3 Readout | — |
| 2027-07-01 | Phase2 Readout | — |
| 2027-07-02 | Phase2 Readout | — |
Active Clinical Trials (19)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT03682536 | A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due... | PHASE3 | Active Not Recruiting | 363 |
| NCT07159763 | A Study to Evaluate the Safety and Efficacy of CD388 for Prevention of Influenza | PHASE3 | Active Not Recruiting | 10,000 |
| NCT07016412 | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | PHASE2 | Recruiting | 480 |
| NCT04081220 | Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2 | PHASE2 | Active Not Recruiting | 9 |
| NCT05270668 | Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With I... | PHASE2 | Active Not Recruiting | 154 |
| NCT04471727 | A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001) | PHASE2 | Active Not Recruiting | 232 |
| NCT03162536 | A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-... | PHASE2 | Active Not Recruiting | 190 |
| NCT06559150 | A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis | PHASE2 | Recruiting | 284 |
| NCT07225959 | A Study to Evaluate the Safety, Pharmacokinetics, and Occurrence of Anti-Drug Antibodies Following Annual Doses of CD388 | PHASE2 | Active Not Recruiting | 400 |
| NCT03401788 | A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Ce... | PHASE2 | Active Not Recruiting | 50 |
| NCT04143724 | Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia | PHASE2 | Recruiting | 99 |
| NCT05270525 | Effect of Ensifentrine on Sputum Markers of Inflammation in COPD | PHASE2 | Recruiting | 56 |
| NCT04262141 | IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV) | PHASE2 | Active Not Recruiting | 4 |
| NCT03634540 | A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinom... | PHASE2 | Active Not Recruiting | 118 |
| NCT02974738 | A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001) | PHASE1 | Active Not Recruiting | 120 |
| NCT02293980 | A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-00... | PHASE1 | Active Not Recruiting | 110 |
| NCT07300085 | A Trial to Evaluate the Effect of CD388 on the Immunogenicity of Fluzone® HD Vaccine | PHASE1 | Active Not Recruiting | 100 |
| NCT04184050 | Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001) | PHASE1 | Active Not Recruiting | 100 |
| NCT05597306 | Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia | PHASE1 | Recruiting | 18 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.